» Articles » PMID: 28042245

Viral Hepatitis Status Does Not Affect Survival in Patients with Hepatocellular Carcinoma

Overview
Specialty Gastroenterology
Date 2017 Jan 3
PMID 28042245
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There have been few studies on the impact of viral etiology on the prognosis in patients with hepatocellular carcinoma (HCC). The aim of this study was to evaluate the clinical characteristics and survival of patients with viral hepatitis-associated HCC (V-HCC), compared to patients with HCC of non-hepatitis B, non-hepatitis C (NBNC-HCC) etiology.

Methods: We performed a retrospective analysis of all patients with HCC treated at our comprehensive cancer center from 2000 through 2014. Patients were divided into two groups according to their viral hepatitis status. Presentation patterns, treatments, and survival data were analyzed.

Results: We evaluated 366 patients: 233 patients (63.7%) had V-HCC while 133 (36.3%) patients had NBNC-HCC. V-HCC patients were younger (P<0.0001) and more likely to be male (P=0.001). Decompensated cirrhosis was more prevalent in V-HCC patients (P=0.01). There was no difference in the resectability rate or disease stage. In patients with resectable disease, those with V-HCC were less likely to undergo hepatectomy (23.7% vs. 38%; P=0.04) for more advanced liver disease. The estimated median survival for V-HCC was 13 months compared to 16 months in NBNC-HCC patients (P=0.57). On multivariate analysis, disease stage (P<0.0001) and Child-Pugh class (P<0.0001) were independent factors affecting survival, but viral status was not (P=0.75).

Conclusion: Despite presenting with more advanced cirrhosis and being less likely to undergo surgery, V-HCC patients had similar survival to patients with NBNC-HCC.

Citing Articles

Authors' reply.

Alkhalili E, Greenbaum A, Luo L, Rodriguez R, Caldwell K, Estrada O Ann Gastroenterol. 2017; 30(4):471.

PMID: 28655992 PMC: 5480008. DOI: 10.20524/aog.2017.0150.


The impact of hepatitis C virus and human immunodeficiency virus coinfection on survival in patients with hepatocellular carcinoma.

Spartalis E, Damaskos C, Athanasiou A, Dimitroulis D Ann Gastroenterol. 2017; 30(4):471.

PMID: 28655991 PMC: 5480007. DOI: 10.20524/aog.2017.0149.

References
1.
Poon D, Anderson B, Chen L, Tanaka K, Lau W, Van Cutsem E . Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol. 2009; 10(11):1111-8. DOI: 10.1016/S1470-2045(09)70241-4. View

2.
Gurtsevitch V . Human oncogenic viruses: hepatitis B and hepatitis C viruses and their role in hepatocarcinogenesis. Biochemistry (Mosc). 2008; 73(5):504-13. DOI: 10.1134/s0006297908050039. View

3.
Sherman M . Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005; 25(2):143-54. DOI: 10.1055/s-2005-871194. View

4.
Trevisani F, Magini G, Santi V, Morselli-Labate A, Cantarini M, Di Nolfo M . Impact of etiology of cirrhosis on the survival of patients diagnosed with hepatocellular carcinoma during surveillance. Am J Gastroenterol. 2007; 102(5):1022-31. DOI: 10.1111/j.1572-0241.2007.01100.x. View

5.
Liu P, Hsu C, Hsia C, Lee Y, Su C, Huang Y . Prognosis of hepatocellular carcinoma: Assessment of eleven staging systems. J Hepatol. 2015; 64(3):601-8. DOI: 10.1016/j.jhep.2015.10.029. View